Browsing Tag
FOLFIRINOX
2 posts
OncoSil Medical (ASX: OSL) rallies as FDA decision window opens
OncoSil is rallying into an FDA decision, but its trial was not designed to prove superiority. Can ASX turn clinical promise into sales?
Amplia Therapeutics (ASX: ATX) shares gain after 31% response rate in pancreatic cancer trial; U.S. Phase 2 greenlit
Amplia Therapeutics’ pancreatic cancer trial hits 31% response rate with narmafotinib. Find out how U.S. expansion plans could reshape the biotech’s pipeline.